艾伯塔省由于质量问题,在2022年药品交易失败后仍欠49M元,没有确认新的供应。 Alberta still owes $49M on a failed 2022 drug deal due to quality issues, with no new supplies confirmed.

艾伯塔省仍在努力履行与土耳其制药商Atabay签订的7 000万美元的2022年合同中的4 900万美元,涉及乙酰胺芬和ibuprofen,因为只有价值2 100万美元的进口药品因剂量和一致性问题获得批准。 Alberta is still working to fulfill $49 million of a $70 million 2022 contract with Turkish drugmaker Atabay for acetaminophen and ibuprofen, after only $21 million worth of imported medication was approved due to dosage and consistency issues. 加拿大卫生部于2024年8月开始审查Atabay的一般乙酰安非他明呈文,但批准日期尚未确定。 Health Canada began reviewing Atabay’s generic acetaminophen submission in August 2024, but no approval date has been set. 自2023年以来,艾伯塔省保健服务部门一直在探索其他替代办法,包括昂贵的静脉注射乙酰胺芬,但没有最后购买。 Since 2023, Alberta Health Services has explored alternatives, including a costly intravenous acetaminophen, with no final purchases made. 与进口商MHCare的新协议允许提前付款适用于今后的订单,但关于毒品、数量或费用的任何决定均未得到确认。 A new agreement with importer MHCare allows prepayments to apply to future orders, but no decisions on drugs, volumes, or costs have been confirmed.